Intest Res.  2018 Apr;16(2):178-193. 10.5217/ir.2018.16.2.178.

Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication)

• Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association

• KMID: 2417670
• DOI: http://doi.org/10.5217/ir.2018.16.2.178

Abstract

Inflammatory bowel disease (IBD) patients are a high-risk population for opportunistic infections. The IBD group of the Chinese Society of Gastroenterology of the Chinese Medical Association organized an expert group to discuss and develop this consensus opinion. This consensus opinion referenced clinical study results from China and other countries to provide guidance for clinical practices. Eight major topics, including cytomegalovirus infection, Epstein-Barr virus infection, viral hepatitis, bacterial infection, Mycobacterium tuberculosis infection, fungal infection, parasitic infection, and vaccines were introduced in this article.

Keyword

Inflammatory bowel disease; Opportunistic infections; Consensus

MeSH Terms

Asian Continental Ancestry Group
Bacterial Infections
China
Clinical Study
Consensus*
Cytomegalovirus Infections
Gastroenterology
Hepatitis
Herpesvirus 4, Human
Humans
Inflammatory Bowel Diseases*
Mycobacterium tuberculosis
Opportunistic Infections*
Vaccines
Vaccines

Figure

• 

  Fig. 1 Histopathology of colonic mucosal tissues (×400). (A) Intranuclear inclusion bodies (arrows, H&E stain). (B) Immunohistochemistry of positively stained cells (arrows).

Reference

1. Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017; 32:769–777. PMID: 27723166.

2. Wu D, Li Y, Wang LY, Li JN, Qian JM. A pilot case control study of opportunistic infections in severe ulcerative colitis. Chin J Pract Intern Med. 2016; 36:482–484.

3. Lu H, Liu AL, Li J, Wu D, Zhao YX, Qian JM. Clinical characteristics of ulcerative colitis complicated with opportunistic infections in elderly patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016; 38:288–293. PMID: 27469913.

4. Qian JM, Yang H. Understanding and progress of opportunistic infections in inflammatory bowel disease. Chin J Gastroenterol Hepatol. 2016; 25:1081–1083.

5. Guo LL, Xu HM. Progress in epidemiological research of human cytomegalovirus infection. Int J Lab Med. 2010; 31:1131–1133.

6. Yi F, Zhao J, Luckheeram RV, et al. The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China. Virol J. 2013; 10:43. DOI: 10.1186/1743-422X-10-43. PMID: 23374225.

7. Takahashi Y, Tange T. Prevalence of cytomegalovirus infection in inflammatory bowel disease patients. Dis Colon Rectum. 2004; 47:722–726. PMID: 15037934.

8. Eyre-Brook IA, Dundas S. Incidence and clinical significance of colonic cytomegalovirus infection in idiopathic inflammatory bowel disease requiring colectomy. Gut. 1986; 27:1419–1425. PMID: 3026932.

9. Cooper HS, Raffensperger EC, Jonas L, Fitts WT Jr. Cytomegalovirus inclusions in patients with ulcerative colitis and toxic dilation requiring colonic resection. Gastroenterology. 1977; 72:1253–1256. PMID: 192627.

10. Li J, Lyu H, Yang H, et al. Preoperative corticosteroid usage and hypoalbuminemia increase occurrence of short-term postoperative complications in Chinese patients with ulcerative colitis. Chin Med J (Engl). 2016; 129:435–441. PMID: 26879017.

11. Li TT, Lv ZS, Wang BM, Zhang J. Relationship between refractory ulcerative colitis and cytomegalovirus infection. World Chin J Digestol. 2010; 18:1174–1177.

12. Domènech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008; 14:1373–1379. PMID: 18452205.

13. Nakase H, Matsumura K, Yoshino T, Chiba T. Systematic review: cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2008; 43:735–740. PMID: 18958541.

14. Boivin G, Handfield J, Toma E, et al. Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. J Clin Microbiol. 1998; 36:2509–2513. PMID: 9705384.

15. Lazzarotto T, Dal Monte P, Landini MP. Recent advances in the diagnosis of cytomegalovirus infection. Ann Biol Clin (Paris). 1996; 54:259–265. PMID: 8949423.

16. Herfarth HH, Long MD, Rubinas TC, Sandridge M, Miller MB. Evaluation of a non-invasive method to detect cytomegalovirus (CMV)-DNA in stool samples of patients with inflammatory bowel disease (IBD): a pilot study. Dig Dis Sci. 2010; 55:1053–1058. PMID: 20165976.

17. Wu GD, Shintaku IP, Chien K, Geller SA. A comparison of routine light microscopy, immunohistochemistry, and in situ hybridization for the detection of cytomegalovirus in gastrointestinal biopsies. Am J Gastroenterol. 1989; 84:1517–1520. PMID: 2556912.

18. Dieterich DT, Rahmin M. Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr. 1991; 4(Suppl 1):S29–S35. PMID: 1848619.

19. Cotte L, Drouet E, Bissuel F, Denoyel GA, Trepo C. Diagnostic value of amplification of human cytomegalovirus DNA from gastrointestinal biopsies from human immunodeficiency virus-infected patients. J Clin Microbiol. 1993; 31:2066–2069. PMID: 8396587.

20. Beaugerie L, Cywiner-Golenzer C, Monfort L, et al. Definition and diagnosis of cytomegalovirus colitis in patients infected by human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14:423–429. PMID: 9170416.

21. Franzin G, Muolo A, Griminelli T. Cytomegalovirus inclusions in the gastroduodenal mucosa of patients after renal transplantation. Gut. 1981; 22:698–701. PMID: 6271652.

22. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006; 101:2857–2865. PMID: 17026558.

23. Yang H, Zhou W, Lv H, et al. The association between CMV viremia or endoscopic features and histopathological characteristics of CMV colitis in patients with underlying ulcerative colitis. Inflamm Bowel Dis. 2017; 23:814–821. PMID: 28426459.

24. Suzuki H, Kato J, Kuriyama M, Hiraoka S, Kuwaki K, Yamamoto K. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol. 2010; 16:1245–1251. PMID: 20222169.

25. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol. 2001; 96:773–775. PMID: 11280549.

26. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res. 2014; 12:5–11. PMID: 25349558.

27. Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007; 13:1516–1521. PMID: 17828781.

28. Rahier JF, Magro F, Abreu C, et al. Second European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8:443–468. PMID: 24613021.

29. Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis. 2004; 10:245–250. PMID: 15290919.

30. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012; 46:51–56. PMID: 21552140.

31. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374:1617–1625. PMID: 19837455.

32. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54:1121–1125. PMID: 16009685.

33. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 32:119–130. PMID: 20412066.

34. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant. 2005; 5:2222–2228. PMID: 16095501.

35. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011; 17:591–597. PMID: 20732435.

36. Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy. 2003; 5:323–335. PMID: 12944239.

37. Sacco R, Bertini M, Bresci G, Romano A, Altomare E, Capria A. Entecavir for hepatitis B virus flare treatment in patients with Crohn's disease. Hepatogastroenterology. 2010; 57:242–245. PMID: 20583421.

38. Loras C, Gisbert JP, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010; 59:1340–1346. PMID: 20577000.

39. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009; 50:653–654. PMID: 19575458.

40. Shu HJ, Li J, Yang H, Qian JM. Risk of hepatitis B virus reactivation in patients with inflammatory bowel disease combined with positive hepatitis B surface antigen after immunosuppressive therapies. Chin J Gastroenterol Hepatol. 2016; 25:1127–1131.

41. Chinese Society of Digestive Diseases. IBD Collaboration Group. Investigation on the safety of infliximab against Crohn's disease. Chinese Society of Digestive Diseases. In : Proceedings of the 9th Congress of Gastroenterology China symposium; Guangdong: Guangdong Medical Association;2009.

42. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101:1834–1840. PMID: 16817843.

43. Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16:925–932. PMID: 20480515.

44. Melmed GY. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009; 15:1410–1416. PMID: 19462435.

45. Liu XQ, Qin L. Treatment strategy of inflammatory bowel disease associated with viral hepatitis. Chin J Gastroenterol Hepatol. 2016; 25:1091–1093.

46. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011; 34:1145–1158. PMID: 21978243.

47. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis. 2007; 13:1450–1451. PMID: 17712837.

48. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004; 53:1363–1365. PMID: 15306601.

49. Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20:2142–2150. PMID: 25072501.

50. López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol. 2013; 19:1342–1348. PMID: 23538480.

51. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33:619–633. PMID: 21416659.

52. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167–185. PMID: 22436845.

53. Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis. 2014; 8:282–287. PMID: 24067604.

54. Papa A, Felice C, Marzo M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis. 2013; 7:113–119. PMID: 22464811.

55. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of antitumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford). 2011; 50:1700–1711. PMID: 21690185.

56. Chinese Society of Hepatology. Chinese Medical Association. Wei L. Chinese Society of Infectious Diseases. Chinese Medical Association. Hou JL. The guideline of prevention and treatment for hepatitis C: a 2015 update. Zhonghua Gan Zang Bing Za Zhi. 2015; 23:906–923. PMID: 26739465.

57. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015; 373:287–288.

58. Li Y, Qian JM. Identification and treatment strategies of inflammatory bowel disease with Clostridium difficile infection. Chin J Gastroenterol Hepatol. 2016; 25:1088–1090.

59. Xun J, Xia B, Peng M, Chen LP, Wang W, Yi FM. Relationship between inflammatory bowel disease and Clostridium difficile infection. Med J Wuhan Univ. 2012; 33:680–683.

60. Jin K, Wang S, Huang Z, Lu S. Clostridium difficile infections in China. J Biomed Res. 2010; 24:411–416. PMID: 23554657.

61. Guo FL, Wen SB, Hu M, Zhang XQ. Comparison of five handhygiene methods for removal of Clostridium difficile. Chin J Disinfection. 2015; 32:737–738.

62. Luciano JA, Zuckerbraun BS. Clostridium difficile infection: prevention, treatment, and surgical management. Surg Clin North Am. 2014; 94:1335–1349. PMID: 25440127.

63. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009; 30:253–264. PMID: 19438424.

64. Trifan A, Stanciu C, Stoica O, Girleanu I, Cojocariu C. Impact of Clostridium difficile infection on inflammatory bowel disease outcome: a review. World J Gastroenterol. 2014; 20:11736–11742. PMID: 25206277.

65. Brown NA, Lebar WD, Young CL, Hankerd RE, Newton DW. Diagnosis of Clostridium difficile infection: comparison of four methods on specimens collected in Cary-Blair transport medium and tcdB PCR on fresh versus frozen samples. Infect Dis Rep. 2011; 3:e5. DOI: 10.4081/idr.2011.e5. PMID: 24470904.

66. Xu R, Ge P, Chen R, Liu XJ. Comparison of three different methods for detection of Clostridium difficile. Lab Med. 2015; 30:201–205.

67. Owens RC. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs. 2007; 67:487–502. PMID: 17352510.

68. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97:1769–1775. PMID: 12135033.

69. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011; (9):CD004610. DOI: 10.1002/14651858.CD004610.pub4. PMID: 21901692.

70. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011; 155:839–847. PMID: 22184691.

71. McDonald EG, Lee TC. Treatment for Clostridium difficile infection in adults. JAMA. 2015; 313:1974–1975. PMID: 25988469.

72. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45:302–307. PMID: 17599306.

73. Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis. 2013; 19:194–204. PMID: 22508484.

74. Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015; 2:e000028. DOI: 10.1136/bmjgast-2014-000028.

75. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5:345–351. PMID: 17368234.

76. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol. 2009; 7:981–987. PMID: 19523534.

77. Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res. 2018; 16:4–16. PMID: 29422793.

78. Jauregui-Amezaga A, Turon F, Ordás I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. 2013; 7:208–212. PMID: 22677117.

79. Abreu C, Magro F, Santos-Antunes J, et al. Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control dpopulation. J Crohns Colitis. 2013; 7:e486–e492. PMID: 23583099.

80. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011; 106:1594–1602. PMID: 21844919.

81. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010; 4:28–62. PMID: 21122489.

82. Expert group on the prevention and management of tuberculosis in the application of tumor necrosis factor antagonists. Expert consensus on the prevention and management of tuberculosis in the use of tumor necrosis factor antagonists. Chin J Rheumatol. 2013; 17:508–512.

83. Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol. 2013; 40:683–695. PMID: 24033880.

84. Kim HA, Yoo CD, Baek HJ, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol. 1998; 16:9–13. PMID: 9543555.

85. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001; 15:423–432. PMID: 11447704.

86. Lai CC, Lee MT, Lee SH, Lee SH, Chang SS, Lee CC. Risk of incident active tuberculosis and use of corticosteroids. Int J Tuberc Lung Dis. 2015; 19:936–942. PMID: 26162360.

87. Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013; 4:167–185. PMID: 23819020.

88. Cardoso IP, de Almeida NP, Gotardo DR, Cardeal M, Santana GO. Tuberculin skin testing in inflammatory bowel disease patients from an endemic area of Brazil. Braz J Infect Dis. 2014; 18:60–64. PMID: 24055308.

89. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015; 46:1563–1576. PMID: 26405286.

90. Shi XC, Zhang LF, Zhang YQ, Liu XQ, Fei GJ. Clinical and laboratory diagnosis of intestinal tuberculosis. Chin Med J (Engl). 2016; 129:1330–1333. PMID: 27231171.

91. Li J, Yang QT, Yue JR, et al. Evaluation of interferon-gamma release assays and tuberculin skin test in screening active tuberculosis and latent tuberculosis infection in close contacts of pulmonary tuberculosis patients. Chin J Antituberc. 2015; 37:748–752.

92. Lin L, Chen YY, Wang SX. The clinical application value of interferon gamma release assays for diagnosis of latent tuberculosis infection in children. Zhejiang Med Educ. 2014; 13:54–56.

93. Zhao SY. Diagnosis and treatment of latent tuberculosis infection in children. Chin J Pract Pediatr. 2003; 18:395–397.

94. Zhang LF, Liu XQ. Advances in clinical applications of T-SPOT. TB for interferon-gamma release assay in the immunodiagnosis of tuberculosis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009; 31:506–510. PMID: 19771743.

95. Peng YL, Liu CY, Zhang HQ, Hou YP, Sun Q. The status of tuberculosis latent infection and analysis to laboratory monitoring indicators in high-risk medical staff. J Clin Pulm Med. 2011; 16:546–547.

96. Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax. 2010; 65:271–276. PMID: 20335301.

97. Amanatidou V, Syridou G, Mavrikou M, Tsolia MN. Latent tuberculosis infection in children: diagnostic approaches. Eur J Clin Microbiol Infect Dis. 2012; 31:1285–1294. PMID: 22215186.

98. Chinese Medical Association Tuberculosis Branch. Chinese Journal of Tuberculosis and Respiratory Diseases Editorial Committee. Suggestion on the application of interferon-gamma release assays in China. Chin J Tuberc Respir Dis. 2014; 37:744–747.

99. Park DI, Hisamatsu T, Chen M, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res. 2018; 16:17–25. PMID: 29422794.

100. Wu D, Yang H, Li Y, Li JN, Qian JM. Clinical features of pulmonary abnormalities associated with inflammatory bowel disease. Chin J Gastroenterol Hepatol. 2016; 25:1132–1135.

101. Niu HJ, Su BZ. Progress of fungi in gut and the related diseases. Chin J Mycol. 2015; 10:377–384.

102. Underhill DM, Iliev ID. The mycobiota: interactions between commensal fungi and the host immune system. Nat Rev Immunol. 2014; 14:405–416. PMID: 24854590.

103. Che Y, Liu K, Li QR. The development of fungal community in intestinal diseases. Parenter Enteral Nutr. 2015; 22:378–381.

104. Li Q, Wang C, Tang C, He Q, Li N, Li J. Dysbiosis of gut fungal microbiota is associated with mucosal inflammation in Crohn's disease. J Clin Gastroenterol. 2014; 48:513–523. PMID: 24275714.

105. Badiee P. Evaluation of human body fluids for the diagnosis of fungal infections. Biomed Res Int. 2013; 2013:698325. DOI: 10.1155/2013/698325. PMID: 23984401.

106. Nawrot U, Kowalska-Krochmal B, Sulik-Tyszka B, et al. Evaluation of blood culture media for the detection of fungi. Eur J Clin Microbiol Infect Dis. 2015; 34:161–167. PMID: 25098681.

107. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10:677–692. PMID: 15472534.

108. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidencebased consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009; 3:47–91. PMID: 21172250.

109. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010; 105:1231–1238. PMID: 20104218.

110. Loras C, Gisbert JP, Saro MC, et al. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohns Colitis. 2014; 8:1529–1538. PMID: 25052345.

111. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107:1460–1466. PMID: 23034605.

112. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55:1–33.

113. WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations. Vaccine. 2010; 28:589–590. PMID: 19896455.

114. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet. 2000; 355:561–565. PMID: 10683019.

115. Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997; 336:196–204. PMID: 8988900.

116. Morisco F, Castiglione F, Rispo A, et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat. 2013; 20:200–208. PMID: 23383659.

117. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012; 18:1042–1047. PMID: 21674732.